Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital - Cornell Medical Center, New York, NY, USA.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital - Cornell Medical Center, New York, NY, USA.
Leuk Res. 2014 May;38(5):517-24. doi: 10.1016/j.leukres.2014.02.008. Epub 2014 Mar 13.
Despite the evolution of effective frontline treatment strategies, many patients with myeloma inevitably relapse. Treatment can be complicated by the interplay of disease-, treatment-, and patient-related factors. Unfortunately, many patients eventually develop disease that is refractory to lenalidomide and bortezomib and have few treatment options. Pomalidomide is a distinct IMiD agent recently approved in the US and Europe. We review the pomalidomide mechanism of action, summarizing its direct antimyeloma, immunomodulatory, and stromal-support inhibitory activities. We also detail its clinical development, including establishment of the approved dose/schedule, phase 2 and 3 trials in relapsed and refractory patients, and novel pomalidomide-based combinations.
尽管有效的一线治疗策略不断发展，但许多骨髓瘤患者仍不可避免地会复发。疾病、治疗和患者相关因素的相互作用会使治疗变得复杂。不幸的是，许多患者最终会发展为对来那度胺和硼替佐米耐药的疾病，且治疗选择有限。泊马度胺是一种新的 IMiD 药物，最近在美国和欧洲获得批准。我们综述了泊马度胺的作用机制，总结了其直接抗骨髓瘤、免疫调节和基质支持抑制作用。我们还详细介绍了其临床开发，包括确定批准的剂量/方案，在复发和难治性患者中的 2 期和 3 期试验，以及新的泊马度胺为基础的联合治疗。
